.jetcityimage/iStock Editorial via Getty Images Morgan Stanley has actually picked Eli Lilly (NYSE: LLY) as its own leading biopharma choice for 2025 and ranked one more 9 labels in the room as over weight. The investment bank pointed out in a note that it remains to strongly believe “diabesity is readied to end up being.